Volume : 12, Issue : 11, November – 2025
Title:
FORMULATION, DEVELOPMENT AND CHARACTERIZATION OF BUCCAL PATCHES OF PINDOLOL
Authors :
Prajwal Gajanan Tekade*, Mr. Mujahid Khan, Dr. Balasubramanium Arumugam
Abstract :
The present study focuses on the formulation and optimization of Pindolol buccal patches using the solvent casting technique for sustained drug delivery. Patches were prepared with HPMC-E15 in combination with Eudragit RLPO, Eudragit RSPO, and Carbopol 934P, using PEG as a plasticizer and ethanol as a solvent. Six formulations (F1–F6) were evaluated for physical characteristics, mechanical properties, swelling index, in vitro residence time, and drug release. All patches were transparent, uniform in thickness (53–60 µm), and exhibited consistent weight (115–120 mg) and drug content (95–99%). Folding endurance ranged from 130 to 192, and surface pH values were near neutral, indicating suitability for buccal application. Swelling studies demonstrated maximum hydration for formulation F4 (63.87%), which also showed the longest in vitro residence time (3.45 h). In vitro release studies of F4 indicated a sustained release of 98.65% over 6 h, with kinetic modeling suggesting non-Fickian release. Overall, F4 was identified as the optimized formulation, demonstrating promising potential as a mucoadhesive buccal delivery system for Pindolol.
Keywords: Pindolol, Buccal Patch, HPMC-E15, Eudragit RLPO, Solvent Casting, Mucoadhesion, Sustained Release.
Cite This Article:
Please cite this article in press Prajwal Gajanan Tekade et al., Formulation, Development And Characterization Of Buccal Patches Of Pindolol, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Katz, A. M., et al. (2019). Cardiovascular pharmacology: basic and clinical aspects. New York: McGraw-Hill.
2. Frishman, W. H., et al. (1980). Pharmacology of pindolol: a nonselective beta-adrenergic receptor blocking agent. Am J Cardiol, 45(4), 763–770.
3. Brunton, L. L., et al. (2018). Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill.
4. Shojaei, A. H. (1998). Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci, 1(1), 15–30.
5. Rathbone, M. J., et al. (2019). Modified-release drug delivery technology. 3rd ed. CRC Press.
6. Kalia, Y. N., et al. (2004). Buccal drug delivery: a promising route for systemic drug administration. Pharm Sci Technol Today, 7(9), 333–341.
7. Chien, Y. W. (2005). Novel drug delivery systems. 2nd ed. CRC Press.
8. Patel, M., et al. (2012). Formulation and evaluation of mucoadhesive buccal patches of propranolol hydrochloride. Int J Pharm Pharm Sci, 4(2), 288–294.
9. Bansal, P., et al. (2011). Mucoadhesive buccal drug delivery systems: a review. Int J Pharm Res, 3(1), 12–25.
10. Hassan, F., et al. (2014). Development and evaluation of mucoadhesive buccal patches of metoprolol. Int J Pharm Sci Res, 5(3), 1015–1022.
11. Khanna, R., et al. (2016). Formulation and evaluation of atenolol mucoadhesive buccal patches. Asian J Pharm, 10(2), 114–120.